Hormonal
GLP-1 and GIP receptor agonists reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established cardiovascular disease, independent of weight loss magnitude.
For patients with type 2 diabetes and existing heart disease, GLP-1 therapies like liraglutide and semaglutide significantly reduce the risk of major cardiovascular events (heart attack, stroke, cardiovascular death). This benefit exists alongside weight loss and may be partly due to direct protective effects on the heart and blood vessels. These drugs are now a standard part of care for high-risk diabetic patients.
Significant reductions in major adverse cardiovascular events (MACE) have been demonstrated with liraglutide (13%), semaglutide (26%), and dulaglutide (10%)... A cardiovascular outcome trial for tirzepatide in those with obesity but without diabetes is pending.
Why this rating
Based on large, long-term randomized controlled outcome trials (LEADER, SUSTAIN-6, SELECT).
Source
A Narrative Review of the Metabolic Benefits of GLP-1 and GIP Receptor Agonists in Obesity
Andrew-Hyun Lee et al. · Healthcare · 2026
DOI 10.3390/healthcare14060734
More from this paper
- GLP-1 and dual GLP-1/GIP receptor agonists (semaglutide, tirzepatide, liraglutide) produce significant, clinically meaningful weight loss (10-21%) and reduce the incidence of type 2 diabetes in adults with overweight or obesity, with effects rivaling metabolic surgery.Strong
- GLP-1 and GIP receptor agonists improve hepatic outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), including resolution of MASH and improvement in fibrosis.Good
- GLP-1 and GIP receptor agonists improve obstructive sleep apnea (OSA) severity, with tirzepatide being the first medical therapy approved for OSA, showing significant reductions in apnea-hypopnea index (AHI).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →